Company intelligence / Profile preview

Danisco

Copenhagen, Denmarkanimalnutrition.iff.com ↗

Ownership: Private
Development stage: Commercial

Overview

Danisco was a global leader in food ingredients, enzymes, and bioproducts with significant activities in pharmaceutical-grade excipients. The company was acquired by DuPont in 2011 for $6.3 billion to strengthen DuPont’s position in industrial biotechnology and specialty food ingredients[1][9][10]. Its R&D contributed to major scientific advances including foundational work on CRISPR mechanisms[1].

Modalities: EnzymeProbioticBiologic
Industry: Non-Drug Biotech

Drug pipeline

2 assets

Axtra PHY

Commercial

Indications: Animal feed

1 more asset in the full pipeline.

Request access →

Partnerships

DuPont Danisco Cellulosic Ethanol LLC joint venture with DuPontGoodyear project for bioIsoprene synthetic rubber

Beyond the preview

Go deeper on Danisco.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Danisco.

Explore the full profile